We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
YCBD icon
12426
CALL
cbdMD
YCBD
$5.2M
$13K ﹤0.01%
83
+9
+12% +$2.13K
ARAV
12427
DELISTED
Aravive, Inc. Common Stock
ARAV
$13K ﹤0.01%
+13,031
New +$17.2K
ORTX
12428
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$13K ﹤0.01%
2,141
-12,990
-86% -$73.3K
ONCT
12429
CALL
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$13K ﹤0.01%
570
-45
-7% -$1K
CZOO
12430
CALL
DELISTED
Cazoo Group Ltd
CZOO
$13K ﹤0.01%
9
-76
-89% -$250K
LMNL
12431
DELISTED
Liminal BioSciences Inc. Common Shares
LMNL
$13K ﹤0.01%
+2,617
New +$17K
GSQB.WS
12432
DELISTED
G Squared Ascend II Inc. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
GSQB.WS
$13K ﹤0.01%
99,624
-302,539
-75% -$79.3K
BLCM
12433
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$13K ﹤0.01%
+11,386
New +$17.2K
DTRTW
12434
DELISTED
DTRT Health Acquisition Corp. Warrant
DTRTW
$13K ﹤0.01%
217,385
-582,645
-73% -$81.2K
SHACW
12435
DELISTED
SCP & CO Healthcare Acquisition Company Warrant
SHACW
$13K ﹤0.01%
164,295
-271,738
-62% -$37.9K
UPH
12436
PUT
DELISTED
UpHealth, Inc.
UPH
$13K ﹤0.01%
2,220
-1,240
-36% -$9.65K
NBEV
12437
CALL
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$13K ﹤0.01%
57,900
-15,800
-21% -$5.97K
ADTX
12438
PUT
DELISTED
ADITXT INC
ADTX
0
AQMS icon
12439
CALL
Aqua Metals
AQMS
$9.99M
$12K ﹤0.01%
73
-70
-49% -$13.7K
CNET icon
12440
ZW Data Action Technologies
CNET
$4.73M
$12K ﹤0.01%
+1,824
New +$15.8K
FRSX
12441
CALL
Foresight Autonomous Holdings
FRSX
$3.87M
$12K ﹤0.01%
+158
New +$15.6K
GNLN icon
12442
Greenlane Holdings
GNLN
$1.22M
0
ITP icon
12443
CALL
IT Tech Packaging
ITP
$2.91M
$12K ﹤0.01%
10,290
+9,130
+787% +$20.9K
PSHG icon
12444
Performance Shipping
PSHG
$21.9M
$12K ﹤0.01%
+1,451
New +$41.6K
PTPI
12445
CALL
DELISTED
Petros Pharmaceuticals
PTPI
$12K ﹤0.01%
58
-16
-22% -$4.01K
HIND
12446
Vyome Holdings
HIND
$15.3M
0
SOGP
12447
Sound Group
SOGP
$47.1M
$12K ﹤0.01%
1,018
-1,440
-59% -$17.6K
WNW icon
12448
Meiwu Technology Co
WNW
$67.4M
-1
Closed -$47.4K
XPL icon
12449
Solitario Resources
XPL
$75.7M
$12K ﹤0.01%
+21,031
New +$14.5K
CSCI
12450
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$12K ﹤0.01%
600
+36
+6% +$901

Similar funds

Ken Griffin's Q2 2022 Portfolio in Review

As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.